BridgeMD
New treatment option for Hip Disease
Official title PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
ClinicalTrials.gov ID: NCT07023094
What this study is testing
What is Ropivacaine 0.2% for PENG Block?
Ropivacaine 0.2% for PENG Block is an investigational medicine, being studied as a potential treatment for hip disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 to 16
You may be able to join if
- Pediatric patients aged between 2 and 16 years.
- Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries
- ASA (American Society of Anesthesiologists) physical status classification: I-III.
- Written informed consent obtained from the patient's legal guardian(s).
You likely can't join if
- Known allergy or hypersensitivity to any of the study medications
- Presence of infection or inflammation at the intended injection site(s) of regional anesthesia.
- Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks.
- Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs.
- Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation.
- History of chronic opioid use or known substance abuse.
See the full eligibility criteria
- Pediatric patients aged between 2 and 16 years.
- Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries
- ASA (American Society of Anesthesiologists) physical status classification: I-III.
- Written informed consent obtained from the patient's legal guardian(s).
- Known allergy or hypersensitivity to any of the study medications
- Presence of infection or inflammation at the intended injection site(s) of regional anesthesia.
- Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks.
- Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs.
- Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation.
- History of chronic opioid use or known substance abuse.
- Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.
The study team makes the final eligibility decision.
Where it's taking place
- Poznan, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years to 16 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Poznan, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.